An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data from 28 major U.S. cancer centers, the researchers examined the association between glucarpidase treatment -- which rapidly clears MTX from the blood -- and outcomes of patients with MTX-induced acute kidney injury (AKI). They found that patients who received glucarpidase had significantly higher chances of kidney recovery compared to those who did not get this treatment.
Read more …Study finds chemotherapy antidote could improve recovery after chemotherapy-induced kidney toxicity
A research team found that implementing point-of-care ultrasounds (POCUS) to assess the viability and gestational age of pregnancies in the first trimester enhanced care for pregnant patients and cut emergency visits by 81% for non-miscarrying patients.
Read more …Ultrasound enhances early pregnancy care, cuts emergency visits by 81%